Brought to you by 
Dutch start-up uniQure nets $85.4mm in US IPO
27 Feb 2014
Executive Summary
Gene therapy start-up uniQure BV netted $85.4mm in its US initial public offering. The company sold 5.4mm ordinary shares (more than the 4.6mm planned) for $17, above its $13-15 price range. Existing investors Forbion, Gilde, and Coller agreed to buy 1.2mm of the IPO shares.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dutch start-up uniQure nets $85.4mm in US IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice